BLINCYTO — Total revenues
Products & Services · Total revenuesAmgen BLINCYTO — Total revenues remained flat by 0.0% to $389.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 28.2%, from $304.00M to $389.75M. Over 2 years (FY 2023 to FY 2025), BLINCYTO — Total revenues shows an upward trend with a 34.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, expanded clinical indications, or higher patient demand for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the specific biopharmaceutical product line within the oncol...
Peer comparison
Comparable to specific product-line revenue disclosures in other large-cap biotechnology or pharmaceutical companies, particularly those focused on oncology or specialty therapeutics.
amgn_segment_blincyto_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $861.00M | $1.22B | $1.56B |
| YoY Change | — | +41.2% | +28.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's blincyto — total revenues?
- Amgen (AMGN) reported blincyto — total revenues of $389.75M in Q4 2025.
- How has Amgen's blincyto — total revenues changed year-over-year?
- Amgen's blincyto — total revenues increased by 28.2% year-over-year, from $304.00M to $389.75M.
- What is the long-term trend for Amgen's blincyto — total revenues?
- Over 2 years (2023 to 2025), Amgen's blincyto — total revenues has grown at a 34.6% compound annual growth rate (CAGR), from $861.00M to $1.56B.
- What does blincyto — total revenues mean?
- The total annual revenue generated from sales of the specific oncology drug product line.